Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma

Clinical Practice Points

• •Peritoneal mesothelioma is much rarer than its pleural counterpart; hence, there is a paucity of data to guide management, which usually follows guidelines available for pleural mesothelioma, despite reported molecular differences between the 2 anatomic sites.
• •A recent randomized clinical trial demonstrated better response rate, progression-free survival and overall survival with dual immunotherapy (ipilimumab and nivolumab) than with cytotoxic chemotherapy in pleural mesothelioma.
• •The clinical and radiological response observed with dual immunotherapy in a patient with peritoneal mesothelioma suggests that this a promising therapeutic approach.